Vincristine Sulphate Pharmachemie Indications/Uses

Vincristine Sulphate Pharmachemie 1 mg/ml solution for injection is used either alone or in conjunction with other oncolytic drugs for the treatment of: Acute lymphocytic leukaemia; Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas; Multiple myeloma; Solid tumours, including (metastatic) breast carcinoma, small cell lung carcinoma; Ewing's sarcoma, embryonal rhabdomyosarcoma, primitive neuro-ectodermal tumours (such as medulloblastoma and neuroblastoma), Wilm's tumour and retinoblastoma; Idiopathic thrombocytopenic purpura.
Patients with true ITP refractory to splenectomy and short-term treatment to adrenocortical steroids may responds to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial result with the additional doses.